ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript [Seeking Alpha]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Seeking Alpha
Ameet Mallik - CEO & Director Conference Call Participants Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Robert Burns H.C. Wainwright & Co, LLC, Research Division Welcome to our fireside chat with ADC Therapeutics. I'm Robert Burns, the Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined now by Ameet Mallik, the CEO of ADC. Ameet, thank you for joining us today. Ameet Mallik CEO & Director Thank you so much. It's a pleasure to be here. Robert Burns H.C. Wainwright & Co, LLC, Research Division So why don't we just dive in. So for those who may be unfamiliar with ADC, could you please provide a brief overview of the company? Ameet Mallik CEO & Director Sure. Yes. So ADC Therapeutics is a commercial stage company focused on antibody drug conjugates, obviously, one of the pioneers. And the focus of our company is really on our CD19-directed approved product, ZYNLONTA. ZYNLONTA is currently approved as a
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics (ADCT) had its price target raised by HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 3/10/26 - Beat
ADCT
Sec Filings
- 3/17/26 - Form EFFECT
- 3/16/26 - Form 424B3
- 3/10/26 - Form S-3
- ADCT's page on the SEC website